National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2013 August 16.
2.
SwitzerSM, MoserEG, RocklerBE, GargSK. Intensive insulin therapy in patients with type 1 diabetes mellitus. Endocrinol Metab Clin North Am, 2012; 41:89–104.
3.
AtkinsonMA, EisenbarthGS, MichelsAW. Type 1 diabetes. Lancet, 2013Jul25[Epub ahead of print]S0140-6736(13)60591-7, 10.1016/S0140-6736(13)60591-7.
4.
AshiyaM, SmithRET. Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov, 2007; 6:777–778.
5.
HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359:1577–1589.
6.
The ADVANCE Collaborative Group:. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008; 358:2560–2572.
7.
SehraD, SehraS, SehraST. Sulfonylureas: do we need to introspect safety again?Expert Opin Drug Saf, 2011; 10:851–861.
8.
PernetA, TrimbleER, KuntschenF, AssalJP, HahnC, RenoldAE. Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab, 1985; 61:247–251.
9.
KellerU, MüllerR, BergerW. Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metab Res, 1986; 18:599–603.
10.
GarrelDR, PicqR, BajardL, HarfoucheM, TourniaireJ. Acute effect of glyburide on insulin sensitivity in type I diabetic patients. J Clin Endocrinol Metab, 1987; 65:896–900.
11.
SimonsonDC, DelpratoS, CastellinoP, GroopL, DeFronzoRA. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients. Diabetes, 1987; 36:136–146.
12.
SchimmackG, DefronzoRA, MusiN. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab, 2006; 8:591–602.
13.
El MessaoudiS, RongenGA, RiksenNP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep, 2013; 15:314.
14.
FranciosiM, LucisanoG, LapiceE, StrippoliGF, PellegriniF, NicolucciA. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One, 2013; 8:e71583.
15.
VellaS, BuetowL, RoyleP, LivingstoneS, ColhounHM, PetrieJR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 2010; 53:809–820.
16.
REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)Identifier NCT01483560http://clinicaltrials.gov/show/NCT01483560. 2013 September 13.
17.
Yki-JärvinenH. Thiazolidinediones. N Engl J Med, 2004; 351:1106–1118.
18.
FaillieJL, PetitP, MontastrucJL, Hillaire-BuysD. Scientific evidence, controversies about pioglitazone, bladder cancer: which lessons can be drawn?Drug Saf, 2013Jul20[Epub ahead of print]10.1007/s40264-013-0086-y.
19.
KawanoY, IrieJ, NakataniH, YamadaS. Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. Intern Med, 2009; 48:1037–1039.
20.
BhatR, BhansaliA, BhadadaS, SialyR. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract, 2007; 78:349–354.
21.
ShimadaA, ShigiharaT, OkuboY, KatsukiT, YamadaY, OikawaY. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev, 2011; 27:951–953.
22.
ShigiharaT, OkuboY, KanazawaY, OikawaY, ShimadaA. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci, 2006; 1079:365–368.
23.
van de LaarFA, LucassenPL, AkkermansRP, van de LisdonkEH, RuttenGE, van WeelC. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care, 2005; 28:154–163.
24.
NeuserD, BensonA, BrücknerA, GoldbergRB, HoogwerfBJ, PetzinnaD. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig, 2005; 25:579–587.
25.
ChanJC, ChanKW, HoLL, FuhMM, HornLC, SheavesR, PaneloAA, KimDK, EmbongM. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care, 1998; 21:1058–1061.
26.
DashS, CrispS, HartnellS, DonaldS, DavenportK, SimmonsD, EvansM. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Res Clin Pract, 2012; 95:e49–e51.
27.
Juntti-BerggrenL, PigonJ, HellströmP, HolstJJ, EfendicS. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes. Diabetes Nutr Metab, 2000; 13:7–12.
28.
Rabasa-LhoretR, BurelleY, DucrosF, BourqueJ, LavoieC, MassicotteD, PéronnetF, ChiassonJL. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated type 1 diabetic subjects. Diabet Med, 2001; 18:739–744.
29.
NagaiE, KatsunoT, MiyagawaJ, KonishiK, MiuchiM, OchiF, KusunokiY, TokudaM, MuraiK, HamaguchiT, NambaM. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J, 2011; 58:869–877.
30.
BaylissWM, StarlingEH. The mechanism of pancreatic secretion. J Physiol, 1902; 28:325–353.
31.
La BarreJ. Sur les possibilités d'un traitement du diabète par l'incrétine. Bull Acad R Med Belg, 1932; 12:620–634.
32.
YalowRS, BersonSA. Immunoassay of endogenous plasma insulin in man. J Clin Invest, 1960; 39:1157–1175.
33.
ElrickH, StimmlerL, HladCJ, AraiY. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab, 1964; 24:1076–1082.
34.
Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044TOC.cfm. 2013 August 30.
35.
Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm. 2013 August 30.
36.
Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000TOC.cfm. 2013 August 30.
37.
Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021919_byetta_toc.cfm. 2013 August 30.
38.
Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm. 2013 August 30.
39.
RolinB, LarsenMO, GotfredsenCF, DeaconCF, CarrRD, WilkenM, KnudsenLB. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab, 2002; 283:E745–E752.
40.
RuttiS, SauterNS, BouzakriK, PrazakR, HalbanPA, DonathMY. In vitro proliferation of adult human beta-cells. PLoS One, 2012; 7:e35801.
41.
HareKJ, VilsbøllT, HolstJJ, KnopFK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab, 2010; 298:E832–E837.
42.
CreutzfeldtWO, KleineN, WillmsB, OrskovC, HolstJJ, NauckMA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36) amide in type 1 diabetic patients. Diabetes Care, 1996; 19:580–586.
43.
GhaziT, RinkL, SherrJL, HeroldKC. Acute metabolic effects of exenatide in patients with type 1 diabetes with, without residual insulin to oral, IV glucose challenges. Diabetes Care, 2013August12[Epub ahead of print]10.2337/dc13-1169.
44.
KielgastU, AsmarM, MadsbadS, HolstJJ. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab, 2010; 95:2492–2496.
45.
KielgastU, KrarupT, HolstJJ, MadsbadS. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care, 2011; 34:1463–1468.
46.
VaranasiA, BelliniN, RawalD, VoraM, MakdissiA, DhindsaS, ChaudhuriA, DandonaP. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol, 2011; 165:77–84.
47.
Hari KumarKV, ShaikhA, PrustyP. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract, 2013; 100:e55–e58.
48.
RotherKI, SpainLM, WesleyRA, DigonBJ3rd, BaronA, ChenK, NelsonP, DoschHM, PalmerJP, Brooks-WorrellB, RingM, HarlanDM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care, 2009; 32:2251–2257.
49.
PettusJ, HirschI, EdelmanS. GLP-1 agonists in type 1 diabetes. Clin Immunol, 2013April17[Epub ahead of print]S1521-6616(13)00097-1, 10.1016/j.clim.2013.04.006.
50.
EllisSL, MoserEG, Snell-BergeonJK, RodionovaAS, HazenfieldRM, GargSK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med, 2011; 28:1176–1181.
51.
GargSK, MoserEG, BodeBW, KlaffLJ, HiattWR, BeatsonC, Snell-BergeonJK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract, 2013; 19:19–28.
52.
GiampietroO, GiampietroC, BartolaLD, MasoniMC, MatteucciE. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Dev Ther, 2013; 7:99–104.
53.
EngelSS, GolmGT, ShapiroD, DaviesMJ, KaufmanKD, GoldsteinBJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol, 2013; 12:3.
54.
MonamiM, DicembriniI, MartelliD, MannucciE. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin, 2011; 27:57–64.
55.
SunF, YuK, WuS, ZhangY, YangZ, ShiL, JiL, ZhanS. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract, 2012; 98:386–395.
56.
SciricaBM, BhattDL, BraunwaldE, StegPG, DavidsonJ, HirshbergB, OhmanP, FrederichR, WiviottSD, HoffmanEB, CavenderMA, UdellJA, DesaiNR, MozensonO, McGuireDK, RayKK, LeiterLA, RazI. the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin, cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013Sep2[Epub ahead of print]10.1056/NEJMoa1307684.
57.
WhiteWB, CannonCP, HellerSR, NissenSE, BergenstalRM, BakrisGL, PerezAT, FleckPR, MehtaCR, KupferS, WilsonC, CushmanWC, ZannadF. the EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med, 2013Sep2[Epub ahead of print]10.1056/NEJMoa1305889.
58.
Liraglutide Effect and Action in Diabetes. Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER)Identifier NCT01179048http://clinicaltrials.gov/ct2/show/NCT01179048. 2013 September 13.
59.
Sitagliptin Cardiovascular Outcome Study (0431-082 AM1) (TECOS)Identifier NCT00790205http://clinicaltrials.gov/ct2/show/NCT007902052013 September 13.
60.
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 DiabetesIdentifier NCT01243424http://clinicaltrials.gov/ct2/show/NCT01243424. 2013 September 13.
61.
AhmadSR, SwannJ. Exenatide and rare adverse events. N Engl J Med, 2008; 358:1970–1971.
62.
ElashoffM, MatveyenkoAV, GierB, ElashoffR, ButlerPC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141:150–156.
63.
ButlerPC, MatveyenkoAV, DryS, BhushanA, ElashoffR. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?Diabetologia, 2010; 53:1–6.
64.
SinghS, ChangHY, RichardsTM, WeinerJP, ClarkJM, SegalJB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med, 2013; 173:534–539.
65.
ButlerAE, Campbell-ThompsonM, GurloT, DawsonDW, AtkinsonM, ButlerPC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013; 62:2595–2604.
66.
HarjaE, LordJ, SkylerJS. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther, 2013; 15:609–618.
67.
KahnSE. Incretin therapy and islet pathology—a time for caution. Diabetes, 2013; 62:2178–2180.
68.
MogensenCE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest, 1971; 28:101–109.
69.
MatherA, PollockC. Glucose handling by the kidney. Kidney Int Suppl, 2011; 120:S1–S6.
70.
DeFronzoRA, DavidsonJA, Del PratoS. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab, 2012; 14:5–14.
71.
ElkinsonS, ScottLJ. Canagliflozin: first global approval. Drugs, 2013; 73:979–988.
72.
Abdul-GhaniMA, DefronzoRA. Dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother, 2013; 14:1695–1703.
73.
Safety, Tolerability. Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy VolunteersIdentifier NCT00836225http://clinicaltrials.gov/ct2/show/NCT008362252013 September 13.
74.
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 WeeksIdentifier NCT00297180http://clinicaltrials.gov/ct2/show/NCT002971802013 September 13.
75.
An Efficacy, Safety, Tolerability Study for TA-7284 in Patients With Type 2 DiabetesIdentifier NCT01022112http://clinicaltrials.gov/ct2/show/NCT010221122013 September 13.
76.
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes MellitusIdentifier NCT01029704http://clinicaltrials.gov/ct2/show/NCT010297042013 September 13.
77.
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusIdentifier NCT00963768http://clinicaltrials.gov/ct2/show/NCT009637682013 September 13.
78.
VasilakouD, KaragiannisT, AthanasiadouE, MainouM, LiakosA, BekiariE, SarigianniM, MatthewsDR, TsapasA. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med, 2013; 159:262–274.
79.
BurkiTK. FDA rejects novel diabetes drug over safety fears. Lancet, 2012; 379:507.
80.
ZambrowiczB, FreimanJ, BrownPM, FrazierKS, TurnageA, BronnerJ, RuffD, ShadoanM, BanksP, MseehF, RawlinsDB, GoodwinNC, MabonR, HarrisonBA, WilsonA, SandsA, PowellDR. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther, 2012; 92:158–169.
81.
HanS, HaganDL, TaylorJR, XinL, MengW, BillerSA, WetterauJR, WashburnWN, WhaleyJM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes, 2008; 57:1723–1729.
82.
FujimoriY, KatsunoK, OjimaK, NakashimaI, NakanoS, Ishikawa-TakemuraY, KusamaH, IsajiM. Sergliflozinetabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol, 2009; 609:148–154.
83.
LuippoldG, KleinT, MarkM, GremplerR. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab, 2012; 14:601–607.
84.
AdeghateE, KalászH. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J, 2011; 5:78–81.
85.
RyanGJ, JobeLJ, MartinR. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther, 2005; 27:1500–1512.
86.
HerrmannK, FriasJP, EdelmanSV, LutzK, ShanK, ChenS, MaggsD, KoltermanOG. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med, 2013; 125:136–144.
87.
RatnerR, WhitehouseF, FinemanMS, StrobelS, ShenL, MaggsDG, KoltermanOG, WeyerC. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes, 2005; 113:199–204.
88.
WeinzimerSA, SherrJL, CengizE, KimG, RuizJL, CarriaL, VoskanyanG, RoyA, TamborlaneWV. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care, 2012; 35:1994–1999.
89.
HoltRI, BarnettAH, BaileyCJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab, 2010; 12:1048–1057.
90.
KalraS, KalraB, AgrawalN, KumarS. Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov, 2011; 5:61–65.
91.
DefronzoRA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care, 2011; 34:789–794.
92.
OoiCP, LokeSC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2012; 12:CD009361.
93.
GargSK, RitchiePJ, MoserEG, Snell-BergeonJK, FresonBJ, HazenfieldRM. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab, 2011; 13:137–143.
94.
AmitaniM, AsakawaA, AmitaniH, InuiA. The role of leptin in the control of insulin-glucose axis. Front Neurosci, 2013; 7:51.
95.
ChouK, PerryCM. Metreleptin: first global approval. Drugs, 2013; 73:989–997.
Effects of Metreleptin in Type 1 Diabetes MellitusIdentifier NCT01268644http://clinicaltrials.gov/show/NCT01268644. 2013 August 29.
98.
CoweySL, QuastM, BelalcazarLM, WeiJ, DengX, GivenR, SinghP. Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer, 2005; 103:2643–2653.
99.
MeierJJ, ButlerAE, GalassoR, RizzaRA, ButlerPC. Increased islet β cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia, 2006; 49:2689–2696.
100.
HoveKD, FærchK, BödvarsdóttirTB, KarlsenAE, PetersenJS, VaagA. Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients—a retrospective analysis. Diabetes Res Clin Pract, 2010; 90:e72–e74.
101.
Boj-CarcellerD, Bocos-TerrazP, Moreno-VernisM, Sanz-ParisA, Trincado-AznarP, Albero-GamboaR. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes, 2011; 2:217–220.
102.
SinghPK, HotaD, DuttaP, SachdevaN, ChakrabartiA, SrinivasanA, SinghI, BhansaliA. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab, 2012; 97:E2105–E2108.
103.
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes (REPAIR-T1D)Identifier NCT01155284http://clinicaltrials.gov/ct2/show/NCT011552842013 August 30.
104.
GargSK. Impact of insulin delivery devices in diabetes care. Diabetes Technol Ther, 2010; 12,Suppl 1:S-1–S-4.
105.
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. The DCCT Research Group. Am J Med, 1991; 90:450–459.
106.
GargSK, MoserE. How basal insulin analogs have changed diabetes care. Diabetes Technol Ther, 2011; 13,Suppl 1:S-1–S-4.
Bhide, GreyJMS, MoserEG, GargSK. A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther, 2013; 15:533–537.
109.
MoserEG, CrewLB, GargSK. Role of continuous glucose monitoring in diabetes management. Avances en Diabetologia, 2010; 26:73–79.
110.
BlevinsTC, BodeBW, GargSK, GrunbergerG, HirschIB, JovanovicL, NardacciE, OrzeckEA, RobertsVL, TamborlaneWV. AACE Continuous Glucose Monitoring Task Force: Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract, 2010; 16:730–745.
